Abstract: Pharmaceutical compositions are described containing carrier particles bearing microparticles of a drug. The drug microparticles may be deposited on the carrier particles, for example, by sublimation. Preferred embodiments of these pharmaceutical compositions are suitable for administration by inhalation or injection. Methods for treating lung infection in patients with cystic fibrosis through inhalation of, for example, calcitriol compositions, are also described.

Abstract: The invention provides compositions of levodopa resulting in extended absorption profiles and methods of treatment using the compositions.

Abstract: Provided are pharmaceutical compositions of fenofibrate, and dosage forms containing them, that include fenofibrate, a polyethylene glycol, and a polyethylene-polypropylene glycol; wherein the compositions are made by subliming a sublimable carrier from a combination of fenofibrate, the polyethylene glycol, and the polyethylene-polypropylene glycol with the sublimable carrier, for example menthol.

Abstract: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol, optionally in the presence of at least one surfactant mixture. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of fenofibrate or another fibrate drug and menthol, wherein the fenofibrate or the other fibrate drug is in intimate association with the menthol, wherein the menthol can be menthol or menthol surfactant mixture.

Abstract: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with a polyethylene glycol and a poloxamer, preferably PEG 1000 and Poloxamer 407. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject the fenofibrate composition of the invention.

Abstract: A zero-order release pharmaceutical dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the zero-order release pharmaceutical dosage form is a solid pharmaceutical dosage form which reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A process for making the zero-order release pharmaceutical dosage form are also provided.

Abstract: A zero-order release pharmaceutical dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the zero-order release pharmaceutical dosage form is a solid pharmaceutical dosage form which reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A process for making the zero-order release pharmaceutical dosage form are also provided.

Abstract: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of a fibrate drug, preferably fenofibrate, intimately associated with a surfactant mixture, preferably a mixture comprising PGE 6000 and poloxamer 407. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject the composition.

Abstract: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol or a surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can be a mixture of a polyethylene glycol and a poloxamer such as PGE 1000 and poloxamer 407.

Abstract: The present invention provides a pharmaceutical dosage form for oral administration to a patient comprising an enterically coated core tablet sheathed in an annular body of compressed powder or granular material. The present invention also provides a pharmaceutical dosage form for co-administration of two or more active pharmaceutical ingredients. The present invention also provides a method comprising administering the dosage form of the present invention to a patient with impaired gastric motility, such as a patient with Parkinson's disease.

Abstract: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.

Abstract: The present invention relates to compositions comprising solutions of drugs in menthol, especially drugs that are poorly soluble in water, and to methods for making such compositions.

Abstract: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.

Abstract: Provided are pharmaceutical dosage forms that include rasagiline formulated and fabricated so that release of rasagiline in the stomach is retarded or inhibited.

Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.

Abstract: The present invention provides enterically coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an even further delay such that substantial release of 6-mercaptopurine does not occur until after a certain period of time following passage through the stomach. Such a period of time is preferably at least one hour after passage through the stomach. Following the delay imparted by the enteric coating and optional delay coating, the formulations exhibit better bioavailability and faster dissolution than previous formulations.

Abstract: Provided are methods of treating bone disease including, but not limited to, osteoporosis, metastatic bone disease, or Paget's disease, by administering a combination of raloxifene and alendronate in a manner that mitigates the formation of ulcerative adverse events.

Abstract: A pharmaceutical composition comprising a nanoparticle and any one of a peptide, a polysaccharide, or a glycoprotein, attached electrostatically thereto, and a pharmaceutically acceptable carrier. Uses of the composition and processes for its preparation.

Abstract: The present invention encompasses compositions for the treatment of Parkinson's disease comprising a therapeutically effective amount of levodopa or a metabolic precursor thereof and at least one dopamine transport inhibitor in sufficient amount to decrease dopamine degradation, wherein the dopamine transport inhibitor is administered to avoid dyskinesia.

Abstract: A solid dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the solid dosage form reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A tool set comprising a columnar punch and a punch assembly comprising an annular punch and core rod, and a tableting process for making the solid dosage form are also provided.